RespireRx Pharmaceuticals (RSPID) Stock Price, News & Analysis

Company Overview

RespireRx Pharmaceuticals, Inc. is a development‐stage biopharmaceutical company focused on the discovery and development of novel therapies for respiratory and central nervous system (CNS) disorders. The company’s research centers on small‐molecule compounds designed to modulate neurotransmitter receptors, with particular emphasis on ampakines—agents that enhance AMPA receptor activity—and cholinesterase inhibitors. These mechanisms aim to stimulate neural pathways involved in breathing regulation and cognitive function.

RespireRx’s lead programs include respiratory stimulants targeting conditions such as opioid‐induced respiratory depression and central sleep apnea. By leveraging the ampakine platform, the company seeks to restore normal respiratory drive without the side effects associated with traditional therapies. In parallel, its cholinesterase inhibitor candidates are being explored for potential applications in neurodegenerative diseases, including Alzheimer’s and Parkinson’s, where cholinergic dysfunction contributes to cognitive decline.

Founded in the mid‐2000s under the name Cortex Pharmaceuticals and rebranded in 2016, RespireRx has advanced its compounds through preclinical studies and early‐stage clinical trials. The company is headquartered in the United States and collaborates with research institutions and contract research organizations to support its development efforts. RespireRx’s management team brings together scientific expertise in neuroscience and respiratory physiology, guiding its strategy to move lead candidates toward later‐stage clinical evaluation.

Looking ahead, RespireRx plans to expand its clinical program pipeline and pursue strategic partnerships to accelerate commercialization. The company continues to engage with regulatory authorities to design pivotal studies that may address unmet medical needs in respiratory insufficiency and cognitive impairment, striving to deliver differentiated therapies for patients worldwide.

Key Stats

• Today's Range: $0.0015 to $0.0015
• 50-Day Range: N/A
• 52-Week Range: $0.01 to $1.50
• Volume: 40,000 shs
• Average Volume: 928,930 shs
• Market Capitalization: $108.41 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RSPID Stock Analysis - Frequently Asked Questions

How have RSPID shares performed this year?

RespireRx Pharmaceuticals' stock was trading at $0.0008 on January 1st, 2025. Since then, RSPID shares have increased by 87.5% and is now trading at $0.0015.

How do I buy shares of RespireRx Pharmaceuticals?

Shares of RSPID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:RSPID
• CIK: N/A
• Web: www.respirerx.com
• Phone: 201 444 4947
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 72,271,000
• Free Float: N/A
• Market Cap: $108.41 thousand
• Optionable: Not Optionable
• Beta: 0.15